Bioavailability and Pharmacodynamic study (phase1) of Disgren EC capsule(Triflusal 300mg)

Trial Profile

Bioavailability and Pharmacodynamic study (phase1) of Disgren EC capsule(Triflusal 300mg)

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Triflusal (Primary)
  • Indications Myocardial infarction; Thromboembolism; Unstable angina pectoris
  • Focus Pharmacokinetics
  • Sponsors Myung In
  • Most Recent Events

    • 06 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top